Skip to search formSkip to main contentSkip to account menu

eravacycline

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Eravacycline (Xerava)--an IV tetracycline for complicated intra-abdominal infections.
2018
2018
FDA Approval of Eravacycline for Complicated Intra-Abdominal Infections
The FDA recently approved eravacycline (Xerava) for treatment of complicated intra-abdominal infections (cIAIs) in adults… 
2017
2017
Fully Synthetic Tetracyclines: Increasing Chemical Diversity to Combat Multidrug-Resistant Bacterial Infections
A convergent total synthesis platform has enabled diverse modifications of the tetracycline chemical space that were previously… 
2017
2017
Title : Identification of a PptT Inhibitor that Kills M . tuberculosis and a Novel Mechanism of Resistance Author Block :
Body: Background: Mtb is the leading cause of death from infection. Essential enzymes that have not yet been targeted in Mtb… 
2017
2017
Crystalline forms of eravacycline
2016
2016
Eravacycline: A New Weapon Against Complicated Intra-Abdominal Infections?
Eravacycline, in development to address the urgent need for new antimicrobial agents, is a synthetic tetracycline analogue… 
2015
2015
Activity of Eravacycline Against Anaerobic Bacteria From Europe Collected in 2013-14
2015
2015
Activity of Eravacycline Against North American and European Enterobacteriaceae , Including Multidrug-Resistant Isolates, Collected in 2013-14
2013
2013
Time to Defervescence as an Early Marker of Clinical Response in Patients with Complicated Intra-abdominal Infections Treated with Eravacycline or Ertapenem
Time to defervescence is displayed graphically by using Kaplan Meier methodology for the MITT population below. 88.9%, 96.7%, and…